Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.